Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
With reference to the Q3 update from November 2[nd] 2023 which reported more than 50% recruited patients to the phase IIb clinical trial HeROPA, Arctic Bioscience is pleased to report that we have now recruited more than 75% of the patients required for the trial.
The HeROPA phase IIb clinical trial of HRO350 - a novel, oral drug candidate for the treatment of mild-to-moderate psoriasis - is ongoing in 5 countries in Europe; UK, Germany, Poland, Finland and Norway. As planned, recruitment speed has increased throughout fall as new clinics have been activated. Recruitment is going particularly well in Germany and Poland.
A total of 519 patients are to be included in the trial. To date, more than 75% of the needed patients have been recruited.
"We are very pleased about the current recruitment speed in our HeROPA clinical trial, which brings us closer to our estimated mid 2024 data read-out." says CEO Christer L. Valderhaug.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.